Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
about
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancerImportance of Estrogenic Signaling and Its Mediated Receptors in Prostate CancerERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cellsInduction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttlingA study to correlate histopathology, biochemical marker and immunohistochemical expression of sex-steroid receptors in prostatic growthProstate cancer immunotherapy at the dawn of the new millennium.Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERβ in prostate cancer cells.The potential health effects of dietary phytoestrogensEstrogen receptor-alpha methylation predicts melanoma progressionEpithelial-mesenchymal transition in prostate cancer: an overview.EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer.Clinical implications and management of oestrogen deficiency in the male.High-grade prostatic intraepithelial neoplasia.Estrogen receptors in prostate development and cancerProstatic intraepithelial neoplasia.Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.Signaling through estrogen receptors modulates telomerase activity in human prostate cancer.Estradiol in elderly men.Estrogen action and prostate cancer.Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivityPC-SPES: a brief overview.Associations between estrogen receptor genetic polymorphisms, smoking status, and prostate cancer risk: a case-control study in Japanese men.Progesterone: the forgotten hormone in men?The role of estrogens and estrogen receptors in normal prostate growth and disease.Loss of epithelial oestrogen receptor α inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout modelsEffects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older MenAntagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.Flavonoids as dietary regulators of nuclear receptor activityRecurrent gene fusions in prostate cancerInduction of proinflammatory response in prostate cancer epithelial cells by activated macrophages.Prostate cancer: the need for biomarkers and new therapeutic targets.Targeting nuclear receptors with marine natural products.Soy isoflavones and prostate cancer: a review of molecular mechanisms.Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men.Prostate cancer prevention: concepts and clinical recommendations.Estrogen and androgen signaling in the pathogenesis of BPH.Involvement of estrogen receptors in prostatic diseases.Mechanisms underlying the dualistic mode of action of major soy isoflavones in relation to cell proliferation and cancer risks.
P2860
Q24648557-76815608-79AF-42E6-8CD8-ED2422202E27Q28077543-15F36C3D-CB46-4D90-8DE0-C5CEB4B469DCQ28115023-C619D2FE-D182-4A44-965B-6CBC01A92241Q28537899-AB56C058-6AC9-428D-8497-DF4B8279EE89Q28656332-D085D46C-9EF5-49BB-BF5C-10A3F338EF72Q30327421-E206D35B-3DF5-46EF-93C9-23F1CC8F9B8DQ30686407-D60E1CEB-C250-4ED8-88F1-072EEDBD1F06Q33405120-B6D23A54-0DBD-41CB-86B3-3B402DBB1EC1Q33660177-FEF90E4D-5055-400B-8080-D2E3C8DB9541Q33676455-64E71F9C-5E5A-4DFC-9B11-1950B776F9B6Q33797076-4DBBD3B7-B744-4DB2-B8A2-7D2B55C6C160Q33798864-84226019-A1BE-4790-B63E-1839D49AFD56Q34211979-3E1EDE6C-79AE-4E55-B51B-0EF704EE5706Q34229298-6F5473D5-E81C-4758-8057-D2E20189B0EAQ34291962-2A08BE75-B529-4DD8-BC2E-961D2BBFE6FCQ34448194-5E2101DE-BF10-47BD-A25D-548A19ADAF77Q34707847-7EE586CB-73B1-4EA9-8EB2-90B46884E0CDQ34775924-9941A9D1-29C4-4515-B80A-49F660970112Q34794033-FE2D7428-1E9F-4B19-BBD1-F8D9C560E407Q34800127-FA71D9AB-8672-4C84-80F5-9F0C7A0B3574Q35099011-4D20ED17-2BB0-4663-AC90-50800E9B5879Q35176093-476CBB61-7C3D-4359-BC4F-5C634A038A9AQ35604672-B39BD2B4-9B3D-4CA4-9A51-A3381176CC5EQ35998616-A6F35EE5-9CDA-46FF-8D08-7D9F2F9B2EB6Q36019559-A04A0370-C7C1-4C55-A61D-7F41FA61C354Q36488068-D1EFCD91-DA93-4997-9F07-DF8F895D68C2Q36819484-CA9802AC-6444-43FE-9823-E70353B6A4EEQ36935566-8691F50F-8774-4147-BF44-A06099A5E856Q37084590-0B933B20-2ED5-47B5-BFC2-E275A57C528DQ37193003-BE01B9F6-B173-401C-8EDB-63AC04A6F6D6Q37194503-38B74E34-AFCB-46AA-8DBE-33A08A8297BAQ37199013-F54784C5-0E6D-4CB0-B7E0-3FD413250162Q37476043-ABC6EECC-6831-4AE1-BA0A-CEB4C044393CQ37621100-8BA7BEAE-C00D-41EC-ACBC-0B0E11FFB66EQ37654590-24174412-9A2D-4FF2-A6DC-3DB70FA08DCDQ37737283-D57A4EAF-C9DF-4DB7-9740-CDBF5CA04CD0Q37766754-C475967D-67AE-44C3-8868-A26EF589AC33Q37828063-35B0858C-3CBA-4773-B179-F38B1114FF09Q37989170-D8BF7AE9-503E-4A9A-828B-4F7374EE3281Q38061846-90451AD8-D9C6-4AB3-9530-76A2F8B6868F
P2860
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
@ast
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
@en
type
label
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
@ast
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
@en
prefLabel
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
@ast
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
@en
P2093
P2860
P1476
Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.
@en
P2093
H Bonkhoff
I Hunsicker
K Remberger
P2860
P304
P356
10.1016/S0002-9440(10)65160-7
P407
P577
1999-08-01T00:00:00Z